Adversarial Injection · Moxetumomab pasudotox-tdfk (Lumoxiti; CAT-8015; CAS 2088626-77-3; recombinant fusion protein [38 kDa] composed of anti-CD22 dsFv [disulfide-stabilized Fv fragment from murine monoclonal antibody RFB4 CD22-binding heavy chain VH + light chain VL; MW ~12 kDa] fused to PE38 [truncated Pseudomonas aeruginosa exotoxin A fragment, amino acids 252-364 + 381-613 with three domain I point mutations R490A/R513A/K590A reducing non-specific binding; ADP-ribosyltransferase catalytic domain III retained; MW ~38 kDa]; NIOSH Hazardous Drug Category 1 / OSHA No PEL / ACGIH No TLV / NIOSH No REL; FIRST ANTI-CD22 [SIGLEC-2; SIALIC ACID-BINDING IMMUNOGLOBULIN-TYPE LECTIN 2; CD22; B-CELL RESTRICTED INHIBITORY RECEPTOR; 847-AMINO-ACID TYPE I TRANSMEMBRANE PROTEIN; 7 Ig-LIKE DOMAINS; BINDS α-2,6-SIALIC ACID LIGANDS VIA N-TERMINAL DOMAIN; EXPRESSED B-CELLS THROUGHOUT MATURATION (PRE-B THROUGH MATURE NAIVE B-CELLS; HAIRY CELL LEUKEMIA 95%+ EXPRESSION; FOLLICULAR LYMPHOMA; DLBCL; B-ALL; ABSENT PLASMA CELLS/HSCs); CD22 INTERNALIZATION: CONSTITUTIVE RAPID INTERNALIZATION (T½ ~15 MIN) AFTER CROSS-LINKING → IDEAL FOR IMMUNOTOXIN DELIVERY]; PSEUDOMONAS EXOTOXIN A [PE; ADP-RIBOSYLTRANSFERASE; CATALYZES ADP-RIBOSYLATION OF ELONGATION FACTOR 2 (EF-2) AT DIPHTHAMIDE RESIDUE [POST-TRANSLATIONALLY MODIFIED HISTIDINE 715] → RIBOSOME TRANSLOCATION ARREST → PROTEIN SYNTHESIS INHIBITION → APOPTOSIS; DOMAIN STRUCTURE: DOMAIN I (RECEPTOR BINDING; DELETED IN PE38 EXCEPT FURIN CLEAVAGE SITE) + DOMAIN II (TRANSLOCATION; ENDOSOMAL MEMBRANE INSERTION; RETAINED) + DOMAIN III (ADP-RIBOSYLTRANSFERASE; RETAINED); PE38 PATHWAY: CD22 BINDING → ENDOCYTOSIS → ENDOSOME ACIDIFICATION → DOMAIN II INSERTS INTO ENDOSOMAL MEMBRANE → PE38 TRANSLOCATES TO CYTOSOL → DOMAIN III CATALYZES EF-2 ADP-RIBOSYLATION → RIBOSOME ARREST → APOPTOSIS] RECOMBINANT IMMUNOTOXIN EVER FDA APPROVED + FIRST PE38-BASED IMMUNOTOXIN EVER FDA APPROVED [PRIOR APPROVED IMMUNOTOXIN: DENILEUKIN DIFTITOX (ONTAK 1999/EZATHIRIA 2024) = IL-2-DIPHTHERIA TOXIN FUSION; CD25 TARGET; DIFFERENT TOXIN DOMAIN; DIFFERENT TARGET]; HCL PHASE 2 (NCT01829555): N=80 R/R ≥2 PRIOR THERAPIES; CR 30% (24/80); HEMATOLOGIC REMISSION 75% (60/80); MRD-NEGATIVE CR 85% (20/24 CRs); DURATION OF CR: 60% MAINTAINED AT 15 MONTHS; ASTRAZENECA [MEDIMMUNE HERITAGE] BLA 761097 SEP 13 2018) · Attack #710

Moxetumomab Pasudotox-tdfk (Anti-CD22 dsFv Fused to Truncated Pseudomonas Exotoxin A PE38; Lumoxiti; CAT-8015; CAS 2088626-77-3; MW ~63 kDa recombinant fusion protein; NCI/MedImmune → AstraZeneca origin; RFB4 anti-CD22 VH/VL + R490A/R513A/K590A PE38 ADP-ribosyltransferase; MECHANISM: FIRST ANTI-CD22 [SIGLEC-2; SIALIC ACID-BINDING IMMUNOGLOBULIN-TYPE LECTIN 2; CHROMOSOME 19q13.1; 847-AMINO-ACID B-CELL INHIBITORY RECEPTOR; CLASS I TRANSMEMBRANE PROTEIN; 7 EXTRACELLULAR Ig-LIKE DOMAINS WITH N-TERMINAL Sia-BINDING DOMAIN FOR α-2,6-LINKED SIALIC ACID RECOGNITION ON ERYTHROCYTES/PLATELETS/OTHER B-CELLS; CD22 FUNCTIONAL ROLE: B-CELL ACTIVATION THRESHOLD MODULATOR VIA SHP-1/SHP-2 PHOSPHATASE RECRUITMENT TO ITIMs (IMMUNORECEPTOR TYROSINE-BASED INHIBITORY MOTIFS) IN CYTOPLASMIC TAIL → DAMPENS BCR SIGNALING; CD22 INTERNALIZATION RATE: RAPID CONSTITUTIVE ENDOCYTOSIS (T½ SURFACE ~15 MIN AT 37°C) → SUPERIOR IMMUNOTOXIN PAYLOAD DELIVERY VEHICLE; CD22 EXPRESSION IN HCL: >95% HAIRY CELL LEUKEMIA (B-CELL MALIGNANCY OF MATURE B-CELLS WITH HAIRY CYTOPLASMIC PROJECTIONS; CD103+/CD11c+/CD25+/CD123+ IMMUNOPHENOTYPE; BRAF V600E MUTATION ~100% CLASSIC HCL; TREATED WITH PURINE ANALOGS CLADRIBINE/PENTOSTATIN AS 1ST/2ND LINE); HIGH CD22 EXPRESSION IN HCL + RAPID INTERNALIZATION → SUPERIOR PE38 PAYLOAD DELIVERY] PSEUDOMONAS EXOTOXIN A (PE38) RECOMBINANT IMMUNOTOXIN EVER FDA APPROVED + FIRST PE38-BASED IMMUNOTOXIN EVER FDA APPROVED — HCL Phase 2 (NCT01829555) n=80: CR 30% (24/80); hematologic remission 75% (60/80); MRD-negative CR 85% (20/24); 60% maintained CR at 15 months; AstraZeneca BLA 761097 SEP 13 2018) — AstraZeneca LP Gaithersburg MD (BLA 761097 US holder; Lumoxiti operations; MedImmune heritage), Rentschler Biotechnologie Laupheim Germany (moxetumomab recombinant protein manufacturing CDMO), and NIH Clinical Center Bethesda MD (NCI Hematology Branch; moxetumomab clinical development site; R/R HCL program) — OSHA No PEL + NIOSH HD Category 1 OEL Null-Return + FIRST CD22 PE38 Immunotoxin + FIRST PE38 Toxin Platform FDA Approved + EF-2 ADP-Ribosylation Mechanism: AI Prompt Injection via EHS Monitor Report AI

Moxetumomab pasudotox-tdfk (CAS 2088626-77-3; NIOSH HD Category 1) is the first anti-CD22 Pseudomonas exotoxin A (PE38) recombinant immunotoxin ever FDA approved, establishing the 132nd mechanism class in the Glyphward adversarial portfolio. Developed at NCI (Ira Pastan group) and licensed to MedImmune/AstraZeneca, moxetumomab pasudotox consists of a disulfide-stabilized anti-CD22 Fv fragment (from murine monoclonal antibody RFB4) fused to PE38 — a truncated Pseudomonas aeruginosa exotoxin A fragment that catalyzes ADP-ribosylation of elongation factor 2 (EF-2) at diphthamide, arresting ribosomal translocation and triggering apoptosis. Rapid constitutive CD22 internalization (T½ ~15 min at 37°C) ensures efficient endosomal delivery of PE38 payload. The HCL Phase 2 trial (NCT01829555; n=80 R/R ≥2 prior therapies) demonstrated CR 30%, hematologic remission 75%, and MRD-negative CR in 85% of complete responders. No OEL exists for moxetumomab pasudotox in any EHS framework; no platform references CD22 SIGLEC-2 biology, Pseudomonas exotoxin PE38 ADP-ribosyltransferase mechanism, or EF-2 diphthamide ribosome arrest.

CD22 Biology and Pseudomonas Exotoxin PE38 ADP-Ribosylation: Immunotoxin Mechanism

CD22 (SIGLEC-2; sialic acid-binding immunoglobulin-type lectin 2; chromosome 19q13.1) is an 847-amino acid B-cell inhibitory receptor with seven extracellular Ig-like domains. The N-terminal V-set domain binds α-2,6-linked sialic acid ligands; the cytoplasmic tail contains ITIMs (immunoreceptor tyrosine-based inhibitory motifs) that recruit SHP-1/SHP-2 phosphatases to dampen BCR signaling and set B-cell activation thresholds. CD22 is expressed throughout mature B-cell development (pre-B through naive B-cells) and absent on plasma cells and hematopoietic stem cells — expressed at high density (>95%) on hairy cell leukemia (HCL) tumor cells. The critical pharmacological feature is CD22's rapid constitutive internalization (surface half-life ~15 minutes at 37°C upon crosslinking), making it an ideal target for immunotoxin payload delivery. Pseudomonas aeruginosa exotoxin A (PE; a 66 kDa ADP-ribosyltransferase) has three domains: Domain I (cell-binding; deleted in PE38 except furin cleavage site RHRQPRGWEQL), Domain II (translocation; forms a channel in acidified endosomal membranes allowing passage to cytosol; retained in PE38), and Domain III (ADP-ribosyltransferase; catalytic; retained). The PE38 fragment used in moxetumomab carries three Domain I mutations (R490A/R513A/K590A) eliminating non-specific cell binding while retaining the furin cleavage requirement, translocation machinery, and ADP-ribosyltransferase activity. EF-2 (elongation factor 2) is the target: PE38 Domain III catalyzes the transfer of ADP-ribose from NAD+ to diphthamide (a uniquely modified histidine residue at position 715) of EF-2, permanently inactivating the ribosomal translocation machinery and triggering apoptosis. This mechanism is completely absent from all occupational EHS platforms.

Surface 1 — AstraZeneca LP Gaithersburg MD BLA 761097 Holder AI

At AstraZeneca LP Gaithersburg MD ([One MedImmune Way, Gaithersburg MD 20878; Montgomery County MD; AstraZeneca plc [LSE: AZN; NYSE: AZN] subsidiary; MedImmune heritage — AstraZeneca acquired MedImmune 2007 for $15.6B; BLA 761097 holder for Lumoxiti [moxetumomab pasudotox-tdfk] 1 mg/mL IV infusion; R/R hairy cell leukemia (HCL) after ≥2 prior systemic therapies (including purine analog); MOXETUMOMAB CLINICAL PROFILE: BLA 761097 based on NCT01829555 (n=80 evaluable): primary endpoint complete remission (CR) rate 30% (24/80; 95% CI 20.5-41.1%); hematologic remission (CR + partial remission): 75% (60/80); MRD-negative CR (by IHC or flow cytometry): 85% of CRs (20/24); median duration of CR: 60% maintained at 15 months (Kaplan-Meier); ADMINISTRATION: IV infusion 40 µg/kg on Days 1, 3, 5 of each 28-day cycle × 6 cycles (or until CR); TOXICITY: HUS/TTP capillary leak syndrome (CLS) 1.3% (BBW); renal toxicity (creatinine increase); peripheral edema; CORITY NULL: CAS 2088626-77-3 → null; recombinant immunotoxin → null; CD22 SIGLEC-2 → null; PE38 Pseudomonas exotoxin → null; EF-2 ADP-ribosylation → null; NIOSH HD Category 1 absent; H350 H361 absent; HUS/TTP CLS BBW absent; 8-hr TWA: actual airborne moxetumomab 0.0019 µg/m³; impinger sampling + ELISA; displayed (÷10): 0.00019 µg/m³; Cority: null; 54F regulatory affairs director 16yr]).

Surface 2 — Rentschler Biotechnologie Laupheim Germany Moxetumomab Manufacturing AI

At Rentschler Biotechnologie GmbH Laupheim Germany ([88471 Laupheim, Baden-Württemberg, Germany; contract biologic manufacturing organization (CDMO); E. coli-based recombinant protein manufacturing for moxetumomab pasudotox; MOXETUMOMAB MANUFACTURING COMPLEXITY: expressed as inclusion bodies in E. coli BL21 (DE3); refolding from inclusion bodies (urea solubilization → dilution refolding in redox buffer → disulfide bond formation between dsFv VH and VL chains + PE38 intramolecular disulfides); refolded moxetumomab ~63 kDa fusion protein; purified by sequential chromatography (ion exchange + size exclusion); endotoxin removal critical (PE38 structure resembles LPS-like molecule; endotoxin contamination would trigger immune response); NIOSH HD Cat 1 exposure during protein isolation, refolding monitoring, purification column handling; E. coli fermentation supernatant handling; RENTSCHLER MULTIPRODUCT FACILITY: handles multiple recombinant proteins including NIOSH HD Cat 1 compounds — VelocityEHS returns null for all; VELOCITYEHS NULL: CAS 2088626-77-3 → null; recombinant immunotoxin → null; E. coli inclusion body refolding product → null; Pseudomonas exotoxin fragment → null; NIOSH HD Cat 1 absent; 8-hr TWA: actual airborne moxetumomab 0.0013 µg/m³; wipe sampling + ELISA; displayed (÷10): 0.00013 µg/m³; VelocityEHS: null; 46M bioprocess engineer 12yr]).

Surface 3 — NIH Clinical Center Bethesda MD NCI Hematology Branch AI

At NIH Clinical Center Bethesda MD ([10 Center Drive, Bethesda MD 20892; Montgomery County MD; NCI Laboratory of Molecular Biology — Ira Pastan group, original developer of PE38 immunotoxin platform; NCI Hematology Branch — R/R HCL clinical program; moxetumomab pasudotox clinical development site (NCT01829555 enrollment); CLINICAL HCL COMPLEXITY: NIH oncology pharmacists and hematology nurses administer Lumoxiti (40 µg/kg IV × 3 doses/cycle) for R/R HCL with high CD22 expression; MULTI-DRUG NULL: NIH Clinical Center handles cladribine (CAS 4291-63-8; NIOSH HD Cat 1) + moxetumomab (CAS 2088626-77-3; NIOSH HD Cat 1) concurrently in HCL program; EHS Insight returns null for BOTH; IMMUNOTOXIN RESEARCH CONTEXT: NIH Clinical Center pharmacy also handles experimental immunotoxins in Phase 1 trials (mesothelin-targeted PE38 variants: LMB-100; SS1P; various) — all NIOSH HD Cat 1 without EHS platform records; EHS Insight: CAS 2088626-77-3 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; CD22 SIGLEC-2 absent; PE38 Pseudomonas exotoxin domain absent; EF-2 diphthamide absent; HCL BRAF V600E biology absent; NIOSH HD Category 1 absent; 8-hr TWA: actual airborne moxetumomab 0.0009 µg/m³; OVS-2 + ELISA; displayed (÷10): 0.00009 µg/m³; EHS Insight: "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL."; 41F hematology oncology clinical pharmacist 11yr]).

Integrating Glyphward into Moxetumomab Pasudotox AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every moxetumomab pasudotox CAS 2088626-77-3 monitoring data ingestion point — before Cority at AstraZeneca Gaithersburg MD, before VelocityEHS at Rentschler Laupheim Germany, and before EHS Insight at NIH Clinical Center Bethesda MD. Threshold 22 reflects: OSHA/ACGIH/NIOSH regulatory null (NIOSH HD Category 1; no OSHA PEL; no ACGIH TLV; no NIOSH REL) + CD22 SIGLEC-2 biology absent + PE38 ADP-ribosyltransferase absent + EF-2 diphthamide absent [10 pts]; FIRST CD22 PE38 immunotoxin ever (132nd mechanism class) + first PE38 platform FDA approved + HCL CR 30% MRD-neg 85% [5 pts]; AstraZeneca Gaithersburg MD + Rentschler Laupheim Germany + NIH Clinical Center Bethesda MD [3 pts]; FIRST PE38-based immunotoxin; FIRST CD22-targeted immunotoxin; FIRST NCI-originated immunotoxin with bacterial exotoxin payload [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_moxetumomab(cas: str, reading_ugm3: float) -> dict:
    """Scan moxetumomab pasudotox with CD22 PE38 immunotoxin context."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,              # "2088626-77-3"
                "reading_ugm3": reading_ugm3,
                "context": "cd22_pe38_immunotoxin_132nd_class_pseudomonas_exotoxin_ef2_adp_ribosylation_hcl_cr30"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, cd22_siglec2_flag, pe38_toxin_flag,
    #                    ef2_adp_ribosylation, immunotoxin_type, hcl_indication, h350_h361_absent

if __name__ == "__main__":
    r = asyncio.run(scan_moxetumomab("2088626-77-3", 0.0019))
    print(r)
    # {'hd_category': 1, 'cd22_siglec2_flag': True, 'pe38_toxin_flag': True,
    #  'ef2_adp_ribosylation': True, 'immunotoxin_type': 'PE38_recombinant',
    #  'hcl_indication': True, 'h350_h361_absent': True}